{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:36:52Z","timestamp":1789144612144,"version":"build-2803163510"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["ESF\/14-BM-A55-0046\/16"],"award-info":[{"award-number":["ESF\/14-BM-A55-0046\/16"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017694","name":"Hermann und Lilly Schilling-Stiftung f\u00fcr Medizinische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research\/Reviews in Mutation Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mrrev.2021.108392","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:43:49Z","timestamp":1628401429000},"page":"108392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["A molecular genetics view on Mucopolysaccharidosis Type II"],"prefix":"10.1016","volume":"788","author":[{"given":"Shalja","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9630-1999","authenticated-orcid":false,"given":"Supansa","family":"Pantoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Petters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-4663","authenticated-orcid":false,"given":"Anand Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7364-7791","authenticated-orcid":false,"given":"Andreas","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-5798","authenticated-orcid":false,"given":"Jan","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mrrev.2021.108392_bib0005","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA), (2020) https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/blog-articles\/26102017-hunter-syndrome-mucopolysaccharidosis-type-ii-eu-incentives-behind-omps\/ (Accessed on 20 January 2020)."},{"key":"10.1016\/j.mrrev.2021.108392_bib0010","first-page":"104","article-title":"A rare disease in two brothers","volume":"10","author":"Hunter","year":"1917","journal-title":"Proc. R. Soc. Med."},{"key":"10.1016\/j.mrrev.2021.108392_bib0015","first-page":"38","article-title":"Gargoylism (Hunter-Hurler disease, dysostosis multiplex, lipochondrodystrophy); prenatal and neonatal bone lesions and their early postnatal evolution","volume":"12","author":"Caffey","year":"1951","journal-title":"Bull. Hosp. Joint Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0020","first-page":"143","article-title":"Hereditary disorders of connective tissue","volume":"35","author":"McKusick","year":"1959","journal-title":"Bull. N. Y. Acad. Med."},{"key":"10.1016\/j.mrrev.2021.108392_bib0025","first-page":"302","article-title":"Inguinal hernia in the HurlerHunter syndrome","volume":"61","author":"Coran","year":"1967","journal-title":"Surgery"},{"key":"10.1016\/j.mrrev.2021.108392_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.mrrev.2021.108392_bib0035","first-page":"203","article-title":"Diff\u00e9renciation biochimique des maladies de Hurler et de Hunter par fractionnement de l\u2019h\u00e9paritine sulfate [Biochemical differentiation of Hurler\u2019s and Hunter\u2019s diseases by fracionation of heparitin sulfate]","volume":"15","author":"Maroteaux","year":"1970","journal-title":"Rev. Eur. Etud. Clin. Biol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00440562","article-title":"Biochemical definition of the mucopolysaccharidoses","volume":"108","author":"Spranger","year":"1970","journal-title":"Z. Kinder-Heilk."},{"key":"10.1016\/j.mrrev.2021.108392_bib0045","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","article-title":"The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase","volume":"70","author":"Bach","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mrrev.2021.108392_bib0050","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","article-title":"Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA","volume":"87","author":"Wilson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mrrev.2021.108392_bib0055","series-title":"GeneReviews\u00ae","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"1993"},{"key":"10.1016\/j.mrrev.2021.108392_bib0060","series-title":"GeneReviews\u00ae","first-page":"1993","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2007"},{"key":"10.1016\/j.mrrev.2021.108392_bib0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/14750708.4.3.231","article-title":"Idursulfase for enzyme-replacement therapy in mucopolysaccharidosis II","volume":"4","author":"Wraith","year":"2007","journal-title":"Therapy"},{"key":"10.1016\/j.mrrev.2021.108392_bib0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","article-title":"A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome","volume":"31","author":"Chung","year":"2014","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0080","unstructured":"Medline Plus Mucopolysaccharidosis type I.I. https:\/\/ghr.nlm.nih.gov\/condition\/mucopolysaccharidosis-type-ii#sourcesforpage (Accessed on 27 October 2020)."},{"key":"10.1016\/j.mrrev.2021.108392_bib0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/21678707.2017.1296761","article-title":"Presentation and treatments for mucopolysaccharidosis type II (MPS II; Hunter syndrome)","volume":"5","author":"Stapleton","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.mrrev.2021.108392_bib0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0753-3322(94)90055-8","article-title":"Hunter syndrome among Jews in Israel","volume":"48","author":"Ben-Simon-Schiff","year":"1994","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mrrev.2021.108392_bib0095","unstructured":"EU Clinical Trial Register https:\/\/www.clinicaltrialsregister.eu\/ (Accessed on 27 October 2020)."},{"key":"10.1016\/j.mrrev.2021.108392_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis Type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2020.01011","article-title":"A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management","volume":"9","author":"Zhou","year":"2020","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.mrrev.2021.108392_bib0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13167-011-0081-2","article-title":"Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases","volume":"2","author":"Scarpa","year":"2011","journal-title":"EPMA J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0125","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.mrrev.2021.108392_bib0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13052-018-0550-5","article-title":"Mucopolysaccharidoses: early diagnostic signs in infants and children","volume":"44","author":"Galimberti","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0140","series-title":"Institute of Medicine, Multiple Sclerosis: Current Status and Strategies for the Future","year":"2001"},{"key":"10.1016\/j.mrrev.2021.108392_bib0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.mrrev.2021.108392_bib0150","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s004390050901","article-title":"Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients","volume":"103","author":"Karsten","year":"1998","journal-title":"Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0160","first-page":"273","article-title":"Gaucher disease: insights from a rare Mendelian disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"key":"10.1016\/j.mrrev.2021.108392_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00690379","article-title":"Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain","volume":"39","author":"Dekaban","year":"1977","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000011246","article-title":"Diagnosis and follow-up of patients with Hunter syndrome in Spain: a Delphi consensus","volume":"97","author":"Gonz\u00e1lez-Guti\u00e9rrez-Solana","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.mrrev.2021.108392_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0259-0","article-title":"Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study","volume":"10","author":"Guffon","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13052-018-0553-2","article-title":"Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know","volume":"44","author":"Filocamo","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2007.00212.x","volume":"96","author":"Schwartz","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0200","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1468-3083.2007.02203.x","article-title":"Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients","volume":"21","author":"Ochiai","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0205","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2229-5178.198772","article-title":"Pebbling of skin: cutaneous marker of Hunter syndrome","volume":"8","author":"Srinivas","year":"2017","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/clinchem\/39.1.163","article-title":"Pitfalls of screening for mucopolysaccharidoses by the dimethylmethylene blue test","volume":"39","author":"Piraud","year":"1993","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0215","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymgme.2018.04.011","article-title":"Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis","volume":"125","author":"Khan","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0220","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01330277."},{"key":"10.1016\/j.mrrev.2021.108392_bib0225","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ymgme.2011.12.011","article-title":"A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots","volume":"105","author":"Tolun","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0230","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","article-title":"A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease)","volume":"24","author":"Voznyi","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0235","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1373\/clinchem.2012.189936","article-title":"High-throughput assay of 9 lysosomal enzymes for newborn screening","volume":"59","author":"Spacil","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0240","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1399-0004.1998.tb02598.x","article-title":"A deletion involving exons 2-4 in the iduronate-2-sulfatase gene of a patient with intermediate Hunter syndrome","volume":"53","author":"Bonucelli","year":"1998","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/humu.20165","article-title":"Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with Mucopolysaccharidosis type II revealed by a rapid PCR-based method","volume":"25","author":"Lualdi","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmg.37.10.e29","article-title":"MPS II in females: molecular basis of two different cases","volume":"37","author":"Cudry","year":"2000","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-92","article-title":"Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study","volume":"8","author":"Guill\u00e9n-Navarro","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmg.2012.11.006","article-title":"Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivation","volume":"56","author":"Pi\u00f1a-Aguilar","year":"2013","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12881-019-0807-x","article-title":"Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl","volume":"20","author":"Semyachkina","year":"2019","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-14-49","article-title":"Deletion Xq27.3q28 in female patient with global developmental delays and skewed X-inactivation","volume":"14","author":"Marshall","year":"2013","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0275","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1073\/pnas.90.24.11830","article-title":"Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase","volume":"90","author":"Braun","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mrrev.2021.108392_bib0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/bj3260243","article-title":"Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue","volume":"326","author":"Millat","year":"1997","journal-title":"Biochem. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0925-4439(02)00166-7","article-title":"Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro","volume":"1588","author":"Daniele","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of \u03b1-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0295","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.mrrev.2021.108392_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-016-0558-0","article-title":"Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome","volume":"12","author":"Chiong","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0305","first-page":"23","article-title":"Newborn screening for hunter disease: a small-scale feasibility study","volume":"14","author":"Ruijter","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.mrrev.2021.108392_bib0310","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/pd.457","article-title":"Prenatal diagnosis of the Hunter syndrome and the introduction of a new fluorimetric enzyme assay","volume":"22","author":"Keulemans","year":"2002","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.mrrev.2021.108392_bib0315","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mrrev.2021.108392_bib0320","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mrrev.2021.108392_bib0325","unstructured":"D.N. Cooper, E.V. Ball, P.D. Stenson, A.D. Phillips, K. Evans, S. Heywood, M.J. Hayden, M.M. Chapman, M.E Mort, L. Azevedo and D.S. Millar, The Human Gene Mutation Database (HGMD\u00ae) Cardiff University (http:\/\/www.hgmd.cf.ac.uk\/ac\/index.ph)."},{"key":"10.1016\/j.mrrev.2021.108392_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/471325","article-title":"Glycosaminoglycan storage disorders: a review","volume":"2012","author":"Coutinho","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.mrrev.2021.108392_bib0335","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/humu.20046","article-title":"General implications for CpG hot spot mutations: methylation patterns of the human iduronate-2-sulfatase gene locus","volume":"23","author":"Tomatsu","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-016-0595-3","article-title":"Comparative studies of vertebrate iduronate 2-sulfatase (IDS) genes and proteins: evolution of A mammalian X-linked gene","volume":"7","author":"Holmes","year":"2017","journal-title":"3 Biotech"},{"key":"10.1016\/j.mrrev.2021.108392_bib0345","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/geno.1993.1406","article-title":"Sequence of the human iduronate 2-sulfatase (IDS) gene","volume":"17","author":"Wilson","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.mrrev.2021.108392_bib0350","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbadis.2006.01.003","article-title":"Identification of nine new IDS alleles in mucopolysaccharidosis II. Quantitative evaluation by real-time RT-PCR of mRNAs sensitive to nonsense-mediated and nonstop decay mechanisms","volume":"1762","author":"Lualdi","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0355","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/molbev\/msi043","article-title":"CpG mutation rates in the human genome are highly dependent on local GC content","volume":"22","author":"Fryxell","year":"2005","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0360","first-page":"1202","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): mutation \u201chot spots\u201d in the iduronate-2-sulfatase gene","volume":"59","author":"Rathmann","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0365","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/sj.ejhg.5201615","article-title":"Differences in methylation patterns in the methylation boundary region of IDS gene in Hunter syndrome patients: implications for CpG hot spot mutations","volume":"14","author":"Tomatsu","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0370","first-page":"1","article-title":"Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G&A (p.Gln293Gln) synonymous variation in a female create exonic splicing","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.mrrev.2021.108392_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<333::AID-HUMU18>3.0.CO;2-G","article-title":"Detection of four novel mutations in the iduronate-2-sulfatase gene. Mutations in brief no. 123","volume":"11","author":"Balzano","year":"1998","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0380","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/humu.1380050114","article-title":"Mutations of the iduronate-2-sulfatase gene in 12 Polish patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"5","author":"Popowska","year":"1995","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0385","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/hmg\/1.9.755","article-title":"Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter syndrome (mucopolysaccharidosis type II) confirmed by in vitro mutagenesis and expression","volume":"1","author":"Crotty","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/humu.1380020313","article-title":"Caveat to genotype-phenotype correlation in mucopolysaccharidosis type II: discordant clinical severity of R468W and R468Q mutations of the iduronate-2-sulfatase gene","volume":"2","author":"Whitley","year":"1993","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0395","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10528-012-9538-9","article-title":"Decreasing activity and altered protein processing of human iduronate-2-sulfatase mutations demonstrated by expression in COS7 cells","volume":"50","author":"Charoenwattanasatien","year":"2012","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0400","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/humu.1380060206","article-title":"Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate-2-sulfatase gene in Japanese patients","volume":"6","author":"Sukegawa","year":"1995","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0405","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jmg.36.1.21","article-title":"Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"36","author":"Li","year":"1999","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000472302","article-title":"Presence of an IDS-related locus (IDS2) in Xq28 complicates the mutational analysis of Hunter syndrome","volume":"3","author":"Bondeson","year":"1995","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0415","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/hmg\/4.4.615","article-title":"Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome","volume":"4","author":"Bondeson","year":"1995","journal-title":"Hum. Molec. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0420","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/humu.1380020603","article-title":"Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene","volume":"2","author":"Hopwood","year":"1993","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0425","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/S1525-0016(16)37297-5","article-title":"Alternative splicing of the human iduronate 2-sulfatase gene and implications in gene therapy","volume":"19","author":"Lee","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mrrev.2021.108392_bib0430","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1005432600871","article-title":"Hunter disease in the Spanish population: molecular analysis in 31 families","volume":"21","author":"Gort","year":"1998","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0435","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/adc.79.3.237","article-title":"Mutation analysis in 57 unrelated patients with MPS II (Hunter\u2019s disease)","volume":"79","author":"Vafiadaki","year":"1998","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.mrrev.2021.108392_bib0440","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/humu.1169","article-title":"Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: new mutations in the iduronate-2-sulfatase (IDS) gene","volume":"18","author":"Filocamo","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0445","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10038-005-0266-4","article-title":"Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II","volume":"50","author":"Kato","year":"2005","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10545-012-9533-7","article-title":"Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations","volume":"36","author":"Pollard","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter syndrome from the structure of iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrrev.2021.108392_bib0460","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s10528-012-9538-9","article-title":"Decreasing activity and altered protein processing of human iduronate-2-sulfatase mutations demonstrated by expression in COS7 cells","volume":"50","author":"Charoenwattanasatien","year":"2012","journal-title":"Biochem. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0465","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/CM9.0000000000000426","article-title":"A boy with mucopolysaccharidosis type II accompanied with a novel variation in heparan-N-sulfatase","volume":"132","author":"Li","year":"2019","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0470","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/hmg\/ddv100","article-title":"Analyses of disease-related GNPTAB mutations define a novel GlcNAc-1-phosphotransferase interaction domain and an alternative site-1 protease cleavage site","volume":"24","author":"Velho","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0475","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1074\/jbc.M112.407676","article-title":"Transport of the GlcNAc-1-phosphotransferase \u03b1\/\u03b2-subunit precursor protein to the Golgi apparatus requires a combinatorial sorting motif","volume":"288","author":"Franke","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0480","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/BJ20040739","article-title":"Analysis of normal and mutant iduronate-2-sulphatase conformation","volume":"386","author":"Parkinson-Lawrence","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-26913-4","article-title":"Lysosomal targeting enhancement by conjugation of glycopeptides containing mannose-6-phosphate glycans derived from glyco-engineered yeast","volume":"8","author":"Kang","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mrrev.2021.108392_bib0490","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1074\/mcp.M116.063636","article-title":"Quantitative proteome analysis of mouse liver lysosomes provides evidence for mannose 6-phosphate-independent targeting mechanisms of acid hydrolases in mucolipidosis II","volume":"16","author":"Markmann","year":"2017","journal-title":"Mol. Cell. Proteomics: MCP"},{"key":"10.1016\/j.mrrev.2021.108392_bib0495","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1874285801610010124","article-title":"Bioinformatic analysis of the human recombinant iduronate 2-Sulfate sulfatase","volume":"31","author":"Morales-\u00c1lvarez","year":"2016","journal-title":"Open Microbiol. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0500","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0925-4439(00)00006-5","article-title":"Expression of five iduronate-2-sulfatase site-directed mutations","volume":"1501","author":"Villani","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0505","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(03)00347-7","article-title":"Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme","volume":"113","author":"Dierks","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.mrrev.2021.108392_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21103448","article-title":"Multiple sulfatase deficiency: a disease comprising mucopolysaccharidosis, sphingolipidosis, and more caused by a defect in posttranslational modification","volume":"21","author":"Schlotawa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(95)90314-3","article-title":"A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency","volume":"82","author":"Schmidt","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.mrrev.2021.108392_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21010114","article-title":"Identification and functional characterization of IDS gene mutations underlying taiwanese Hunter syndrome (Mucopolysaccharidosis Type II)","volume":"21","author":"Lin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0525","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pro.5560020704","article-title":"Effects of alanine substitutions in alpha-helices of sperm whale myoglobin on protein stability","volume":"2","author":"Pinker","year":"1993","journal-title":"Protein Sci.: Publ. Protein Soc."},{"key":"10.1016\/j.mrrev.2021.108392_bib0530","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biochi.2015.03.018","article-title":"Taming molecular flexibility to tackle rare diseases","volume":"113","author":"Cubellis","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.mrrev.2021.108392_bib0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2019.01.009","article-title":"Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type II: functional characterization of seven novel IDS variants","volume":"491","author":"Zhang","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0540","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/bip.20960","article-title":"Roles of beta-turns in protein folding: from peptide models to protein engineering","volume":"89","author":"Marcelino","year":"2008","journal-title":"Biopolymers"},{"key":"10.1016\/j.mrrev.2021.108392_bib0545","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00439-004-1234-3","article-title":"Expression studies of mutations underlying Taiwanese Hunter syndrome (mucopolysaccharidosis type II)","volume":"116","author":"Chang","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0550","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1399-0004.1998.tb02746.x","article-title":"Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients","volume":"53","author":"Froissart","year":"1998","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-153X-7-44","article-title":"The multiple roles of histidine in protein interactions","volume":"7","author":"Liao","year":"2013","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6807-10-S1-S5","article-title":"Discrimination of thermophilic and mesophilic proteins","volume":"10","author":"Taylor","year":"2010","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0565","doi-asserted-by":"crossref","first-page":"19714","DOI":"10.1074\/jbc.M114.549915","article-title":"Endoplasmic reticulum-associated degradation of Niemann-Pick C1: evidence for the role of heat shock proteins and identification of lysine residues that accept ubiquitin","volume":"289","author":"Nakasone","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0570","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","article-title":"Structure-function relationships in alpha-galactosidase A","volume":"96","author":"Garman","year":"2007","journal-title":"Acta Paediatr. (Oslo, Norway: 1992)"},{"issue":"2009","key":"10.1016\/j.mrrev.2021.108392_bib0575","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.mrrev.2021.108392_bib0580","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.mrrev.2021.108392_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cge.13583","article-title":"Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): insights from the international MPS I registry","volume":"96","author":"Clarke","year":"2019","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0595","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Genotype\u2013phenotype correlation in Fabry disease","author":"Ries","year":"2006"},{"key":"10.1016\/j.mrrev.2021.108392_bib0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0071894","article-title":"Fabry disease - underestimated in the differential diagnosis of multiple sclerosis?","volume":"8","author":"B\u00f6ttcher","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mrrev.2021.108392_bib0605","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/hmg\/1.5.335","article-title":"Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Bunge","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0610","first-page":"597","article-title":"Molecular diagnosis of mucopolysaccharidosis type II (Hunter syndrome) by automated sequencing and computer-assisted interpretation: toward mutation mapping of the iduronate-2-sulfatase gene","volume":"56","author":"Jonsson","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0615","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.185.4154.862","article-title":"Amino acid difference formula to help explain protein evolution","volume":"185","author":"Grantham","year":"1974","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.mrrev.2021.108392_bib0620","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0625","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0871-8","article-title":"Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II","volume":"9","author":"Osaki","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0635","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0925-4439(01)00075-8","article-title":"The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II","volume":"1537","author":"Bonuccelli","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0640","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0925-4439(97)00096-3","article-title":"COS cell expression studies of P86L, P86R, P480L and P480Q Hunter\u2019s disease-causing mutations","volume":"1406","author":"Millat","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0650","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/humu.22910","article-title":"Functional and clinical consequences of novel \u03b1-galactosidase A mutations in fabry disease","volume":"37","author":"Lukas","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0655","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/humu.21530","article-title":"A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease","volume":"32","author":"Wu","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mrrev.2021.108392_bib0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0665","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","article-title":"Multidisciplinary management of Hunter syndrome","volume":"124","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"issue":"1982","key":"10.1016\/j.mrrev.2021.108392_bib0670","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0675","first-page":"57","article-title":"Three adult siblings with mucopolysaccharidosis type II (Hunter syndrome): a report on clinical heterogeneity and 12 months of therapy with idursulfase","volume":"1","author":"Tchan","year":"2011","journal-title":"JIMD Rep."},{"key":"10.1016\/j.mrrev.2021.108392_bib0680","first-page":"125","article-title":"Report of a Large Brazilian Family With a Very Attenuated Form of Hunter Syndrome (MPS II)","volume":"4","author":"Quaio","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.mrrev.2021.108392_bib0685","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1378\/chest.08-2246","article-title":"Genetic analysis of Rwandan patients with cystic fibrosis-like symptoms: identification of novel cystic fibrosis transmembrane conductance regulator and epithelial sodium channel gene variants","volume":"135","author":"Mutesa","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.mrrev.2021.108392_bib0690","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.a.38551","article-title":"Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"176","author":"Ficicioglu","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.mrrev.2021.108392_bib0695","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cge.12927","article-title":"Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II","volume":"91","author":"Dvorakova","year":"2017","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0700","first-page":"133","article-title":"Practical management of genetic conditions","volume":"4","author":"Tanpaiboon","year":"2019","journal-title":"Transl. Sci. Rare Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0705","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","article-title":"Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)","volume":"126","author":"Wasserstein","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21020400","article-title":"Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses","volume":"21","author":"Sato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0715","first-page":"274","article-title":"Pharmacotherapy of gaucher disease: current and future options","volume":"43","author":"Bennett","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.mrrev.2021.108392_bib0720","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","article-title":"Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy","volume":"56","author":"Lenders","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21030956","article-title":"Assessment of gene variant amenability for pharmacological chaperone therapy with 1-deoxygalactonojirimycin in fabry disease","volume":"21","author":"Lukas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0730","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0735","unstructured":"clinicaltrials.gov."},{"key":"10.1016\/j.mrrev.2021.108392_bib0740","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/gim.2017.30","article-title":"Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review","volume":"19","author":"Bradley","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.mrrev.2021.108392_bib0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0750","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0755","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.mrrev.2021.108392_bib0760","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10545-012-9472-3","article-title":"Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease","volume":"35","author":"Marchesan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0765","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10719-014-9523-0","article-title":"A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome","volume":"31","author":"Chung","year":"2014","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09809-3","article-title":"The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells","volume":"10","author":"Tian","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mrrev.2021.108392_bib0775","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/nbt.2427","article-title":"A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes","volume":"30","author":"Tiels","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0780","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0785","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0790","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF00711365","article-title":"Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease","volume":"17","author":"Brady","year":"1994","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.mrrev.2021.108392_bib0795","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0800","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Pompe disease newborn screening working group, management of confirmed newborn-screened patients with pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.mrrev.2021.108392_bib0805","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2014.05.013","article-title":"Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0810","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mrrev.2021.108392_bib0815","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mrrev.2021.108392_bib0820","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/hmg\/9.7.1087","article-title":"Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann\u2013Pick C disease mouse","volume":"9","author":"Liu","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mrrev.2021.108392_bib0825","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease","volume":"6","author":"Bassett","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.mrrev.2021.108392_bib0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-16-26","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway","volume":"16","author":"Jak\u00f3bkiewicz-Banecka","year":"2009","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mrrev.2021.108392_bib0835","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gene.2016.03.029","article-title":"Cell cycle is disturbed in mucopolysaccharidosis type II fibroblasts, and can be improved by genistein","volume":"585","author":"Moskot","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.mrrev.2021.108392_bib0840","doi-asserted-by":"crossref","first-page":"21200","DOI":"10.1073\/pnas.1119181109","article-title":"Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease","volume":"108","author":"Lu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mrrev.2021.108392_bib0845","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1073\/pnas.1014890108","article-title":"Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts","volume":"108","author":"Pipalia","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mrrev.2021.108392_bib0850","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1476-5381.2009.00565.x","article-title":"Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II","volume":"159","author":"Friso","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0855","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)","volume":"155A","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.mrrev.2021.108392_bib0860","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses","volume":"14","author":"Piotrowska","year":"2006","journal-title":"Eur. J. Hum. Genet.: EJHG"},{"key":"10.1016\/j.mrrev.2021.108392_bib0865","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.curtheres.2008.04.002","article-title":"Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients","volume":"69","author":"Piotrowska","year":"2008","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.mrrev.2021.108392_bib0870","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13052-018-0564-z","article-title":"New treatments for the mucopolysaccharidoses: from pathophysiology to therapy","volume":"44","author":"Fecarotta","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.mrrev.2021.108392_bib0875","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic options for mucopolysaccharidoses: current and emerging treatments","volume":"79","author":"Sawamoto","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mrrev.2021.108392_bib0880","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1210\/en.2004-0102","article-title":"Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 5\u2019-monophosphate-dependent mechanism","volume":"145","author":"Liu","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.mrrev.2021.108392_bib0885","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/17460875.2.1.55","article-title":"Soy protein, soybean isoflavones and coronary heart disease risk: Where do we stand?","volume":"2","author":"Messina","year":"2007","journal-title":"Future Lipidol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0890","first-page":"48","article-title":"Role of histone deacetylases in fungal phytopathogenesis: a review","volume":"4","author":"Cuperlovic-Culf","year":"2014","journal-title":"Int. J. Mod. Bot."},{"key":"10.1016\/j.mrrev.2021.108392_bib0895","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1111\/febs.12505","article-title":"The potential of histone deacetylase inhibitors in Niemann - Pick type C disease","volume":"280","author":"Maceyka","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.mrrev.2021.108392_bib0900","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1074\/mcp.M116.064949","article-title":"Quantitative analysis of the proteome response to the histone deacetylase inhibitor (HDACi) vorinostat in Niemann-Pick type C1 disease","volume":"16","author":"Subramanian","year":"2017","journal-title":"Mol. Cell. Proteomics: MCP"},{"key":"10.1016\/j.mrrev.2021.108392_bib0905","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1074\/jbc.RA119.010524","article-title":"Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid","volume":"295","author":"Subramanian","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mrrev.2021.108392_bib0910","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbapap.2006.08.012","article-title":"Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs","volume":"1764","author":"Arakawa","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.mrrev.2021.108392_bib0915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21020489","article-title":"Pharmacological chaperones: a therapeutic approach for diseases caused by destabilizing missense mutations","volume":"21","author":"Liguori","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2006","key":"10.1016\/j.mrrev.2021.108392_bib0920","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mrrev.2021.108392_bib0925","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409813517663","article-title":"Lysosomal storage diseases","volume":"2","author":"Alroy","year":"2014","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.mrrev.2021.108392_bib0935","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0940","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.mrrev.2021.108392_bib0945","unstructured":"European Medicines Agency, Science Medicine Health https:\/\/www.ema.europa.eu\/en\/documents\/overview\/galafold-epar-summary-public_en.pdf."},{"key":"10.1016\/j.mrrev.2021.108392_bib0950","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","article-title":"Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II","volume":"123","author":"Hoshina","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.mrrev.2021.108392_bib0955","article-title":"Invitro profiling of chondroitin\/dermatan trisulphate disaccharide profiling as pharmacological chaperone for mucopolysaccharidoses type II","author":"Omar","year":"2020","journal-title":"Zenodo"}],"container-title":["Mutation Research\/Reviews in Mutation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574221000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574221000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:23:18Z","timestamp":1761301398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383574221000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":191,"alternative-id":["S1383574221000296"],"URL":"https:\/\/doi.org\/10.1016\/j.mrrev.2021.108392","relation":{},"ISSN":["1383-5742"],"issn-type":[{"value":"1383-5742","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A molecular genetics view on Mucopolysaccharidosis Type II","name":"articletitle","label":"Article Title"},{"value":"Mutation Research\/Reviews in Mutation Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrrev.2021.108392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108392"}}